München
25.11.25 | 08:01
18,700 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:30 | Leerink Partners raises Nanobiotix stock price target to $26 on pipeline progress | 1 | Investing.com | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| Mo | Nanobiotix S.A. provides Q3 Operational and Financial Update | 1 | Seeking Alpha | ||
| Mo | Nanobiotix S.A.: Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook | 77 | GlobeNewswire (Europe) | Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty ("HCRx") of a non-dilutive royalty financing valued up to $71 millionProgress in the... ► Artikel lesen | |
| Mo | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Mo | Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue | 1 | The Motley Fool | ||
| 14.11. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 3 | GlobeNewswire (USA) | ||
| 13.11. | Nanobiotix S.A.: NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations | 4 | GlobeNewswire (USA) | ||
| 12.11. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.11. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 31.10. | Cash-strapped Nanobiotix finds fresh way to source cash from J&J-partnered cancer drug | 12 | FierceBiotech | ||
| 31.10. | Nanobiotix S.A.: NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth | 215 | GlobeNewswire (Europe) | $71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes... ► Artikel lesen | |
| 24.10. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 8 | SEC Filings | ||
| 24.10. | Nanobiotix S.A.: NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control | 282 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen | |
| 15.10. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 15.10. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 3 | GlobeNewswire (USA) | ||
| 06.10. | Jefferies raises Nanobiotix stock price target to EUR21.00 on broad cancer potential | 25 | Investing.com | ||
| 06.10. | Nanobiotix: Jefferies erhöht Kursziel auf 21,00 EUR wegen breiten Krebstherapie-Potenzials | 18 | Investing.com Deutsch | ||
| 02.10. | Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug | 6 | Seeking Alpha | ||
| 02.10. | Nanobiotix stock jumps on positive esophageal cancer treatment data | 2 | Investing.com | ||
| 02.10. | Positive Studiendaten zu Speiseröhrenkrebs-Therapie beflügeln Nanobiotix-Aktie | 10 | Investing.com Deutsch |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 18,600 | -7,00 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,740 | -2,79 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 62,86 | -2,12 % | Halozyme Therapeutics, Inc.: Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery | Royalty revenue contribution expected to begin as early as 2030
Initial partner targets include derisked MoAs that are approved blockbusters today
Highly scalable... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ABCELLERA BIOLOGICS | 3,103 | 0,00 % | Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? | ||
| GLOW LIFETECH | 0,025 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Record Q3 2025 Financial Results; 193% YoY Revenue Growth and Achieves First Positive Cash Flow from Operations | Toronto, Ontario--(Newsfile Corp. - November 25, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the third... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 285,70 | +2,00 % | Biodesix, Inc.: Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays | LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer | The newly created role marks a major step in CEO Kenneth Bilenberg's vision to scale Avid for its next chapter of growth.
TUSTIN, Calif., Nov. 10, 2025 /PRNewswire/... ► Artikel lesen | |
| BIOLINERX | 2,790 | +8,56 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,730 | -9,90 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,180 | -4,22 % | Minerva Neurosciences, Inc: Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors | BURLINGTON, Mass., Nov. 19, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,219 | -2,40 % | Applied Therapeutics prüft strategische Optionen und kündigt Stellenabbau an | ||
| OVID THERAPEUTICS | 1,350 | +4,65 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results | Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT)... ► Artikel lesen | |
| GEOVAX LABS | 0,379 | -0,39 % | GeoVax GAAP EPS of -$0.31 misses by $0.04 |
Das Unternehmen NANOBIOTIX SA ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 18,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.